Abstract
Topical application of eye drops may cause mild or severe adverse ocular or systemic effects. Children, particularly infants, are more prone to systemic adverse effects of topical eye drops because of their lower body mass and blood volume, immature metabolism, and immaturity of excretory, nervous, and cardiovascular systems. Early recognition of signs and symptoms of systemic toxicity is very important. Most of the signs and symptoms can resolve spontaneously; however, in severe cases, physostigmine treatment may be required. Respiratory distress is a rare adverse effect of cyclopentolate. We report an infant who developed respiratory distress after ocular instillation of cyclopentolate and was successfully treated with physostigmine. The benefit of physostigmine use with close follow-up should be borne in mind in cases with a life-threatening cyclopentolate adverse effect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
